78 related articles for article (PubMed ID: 26721816)
1. Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.
Smits MM; Bunck MC; Diamant M; Corner A; Eliasson B; Heine RJ; Smith U; Yki-Järvinen H; van Raalte DH
Diabetes Care; 2016 Mar; 39(3):e42-3. PubMed ID: 26721816
[No Abstract] [Full Text] [Related]
2. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
[TBL] [Abstract][Full Text] [Related]
3. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
4. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.
Xiao C; Bandsma RH; Dash S; Szeto L; Lewis GF
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1513-9. PubMed ID: 22492091
[TBL] [Abstract][Full Text] [Related]
5. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
6. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
7. Exenatide: a novel approach for treatment of type 2 diabetes.
Mikhail N
South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
[TBL] [Abstract][Full Text] [Related]
8. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
9. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
10. Incretins: a new treatment option for type 2 diabetes?
Geelhoed-Duijvestijn PH
Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
[TBL] [Abstract][Full Text] [Related]
11. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Linnebjerg H; Park S; Kothare PA; Trautmann ME; Mace K; Fineman M; Wilding I; Nauck M; Horowitz M
Regul Pept; 2008 Nov; 151(1-3):123-9. PubMed ID: 18675854
[TBL] [Abstract][Full Text] [Related]
12. The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Crouch B; Jones KL; Horowitz M; Rayner CK
Diabetes; 2016 Jan; 65(1):269-75. PubMed ID: 26470783
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
[TBL] [Abstract][Full Text] [Related]
14. Acute glucagon induces postprandial peripheral insulin resistance.
Patarrão RS; Lautt WW; Macedo MP
PLoS One; 2015; 10(5):e0127221. PubMed ID: 25961284
[TBL] [Abstract][Full Text] [Related]
15. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Gallwitz B
Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
[TBL] [Abstract][Full Text] [Related]
16. Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic.
Kutina AV; Marina AS; Shakhmatova EI; Natochin YV
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):510-7. PubMed ID: 23692186
[TBL] [Abstract][Full Text] [Related]
17. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects.
Knop FK; Konings E; Timmers S; Schrauwen P; Holst JJ; Blaak EE
Diabet Med; 2013 Oct; 30(10):1214-8. PubMed ID: 23663119
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Fineman MS; Mace KF; Diamant M; Darsow T; Cirincione BB; Booker Porter TK; Kinninger LA; Trautmann ME
Diabetes Obes Metab; 2012 Jun; 14(6):546-54. PubMed ID: 22236356
[TBL] [Abstract][Full Text] [Related]
19. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
20. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Kolterman OG; Buse JB; Fineman MS; Gaines E; Heintz S; Bicsak TA; Taylor K; Kim D; Aisporna M; Wang Y; Baron AD
J Clin Endocrinol Metab; 2003 Jul; 88(7):3082-9. PubMed ID: 12843147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
